| Not Yet Recruiting | Phosphorus-31 Spectroscopy in Phosphate Diabetes NCT06921720 | Hospices Civils de Lyon | N/A |
| Recruiting | A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia NCT06525636 | Kyowa Kirin Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Baby Detect : Genomic Newborn Screening NCT05687474 | Centre Hospitalier Universitaire de Liege | — |
| Completed | A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth NCT05181839 | Kyowa Kirin Pharmaceutical Development Ltd | — |
| Completed | Anti-FGF23 (Burosumab) in Adult Patients With XLH NCT04695860 | Wuerzburg University Hospital | Phase 3 |
| Active Not Recruiting | Burden of Disease and Functional Impairment in XLH NCT04946409 | Wuerzburg University Hospital | — |
| Completed | Foot Disorders in X-linked Hypophosphatemia NCT06067932 | Orthopedic Hospital Vienna Speising | — |
| Completed | Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH an NCT04273490 | University of Aarhus | — |
| Completed | Examining the Effect of Burosumab on Muscle Function NCT04146935 | Yale University | Phase 4 |
| Unknown | Dental Implants in Patients With X-linked Hypophosphatemia NCT03879915 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | Calcitriol Monotherapy for X-Linked Hypophosphatemia NCT03748966 | Massachusetts General Hospital | EARLY_Phase 1 |
| Completed | Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH NCT03920072 | Kyowa Kirin Pharmaceutical Development Ltd | Phase 3 |
| Completed | X-linked Hypophosphatemia and FGF21 NCT03596554 | Hospices Civils de Lyon | — |
| Completed | FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP) NCT03489993 | Wake Forest University Health Sciences | — |
| Active Not Recruiting | X-linked Hypophosphatemia Disease Monitoring Program NCT03651505 | Ultragenyx Pharmaceutical Inc | — |
| Active Not Recruiting | Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collabora NCT03745521 | Kyowa Kirin Co., Ltd. | — |
| Unknown | Burosumab in Children and Adolescents With X-linked Hypophosphatemia NCT04419363 | Bicetre Hospital | Phase 4 |
| Recruiting | Registry for Patients With X-Linked Hypophosphatemia NCT03193476 | Kyowa Kirin Pharmaceutical Development Ltd | — |
| Unknown | Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosph NCT03820518 | Peking Union Medical College Hospital | Phase 4 |
| Completed | Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients Wi NCT02915705 | Kyowa Kirin, Inc. | Phase 3 |
| Completed | Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-link NCT02750618 | Kyowa Kirin, Inc. | Phase 2 |
| Completed | Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) NCT02537431 | Kyowa Kirin, Inc. | Phase 3 |
| Completed | Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) NCT02526160 | Kyowa Kirin, Inc. | Phase 3 |
| Completed | Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) NCT02312687 | Kyowa Kirin, Inc. | Phase 2 |
| Completed | Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 NCT02163577 | Kyowa Kirin, Inc. | Phase 2 |
| Completed | An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia NCT01571596 | Kyowa Kirin Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia NCT01340482 | Kyowa Kirin Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Study of KRN23 in X-linked Hypophosphatemia NCT00830674 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Available | Expanded Access to Burosumab NCT03775187 | Kyowa Kirin Co., Ltd. | — |